Daher Paul, Bourgi Ali, Riachy Edward, Khoury Antoine, Rehayem Caline, Sader-Ghorra Claude
Departments of *Pediatric Surgery †Pathology, Hotel-Dieu de France University Hospital, Boulevard Alfred Naccache, Achrafieh, Beirut, Lebanon.
J Pediatr Hematol Oncol. 2014 Jul;36(5):e285-9. doi: 10.1097/MPH.0000000000000118.
Renal medullary carcinoma (RMC) is a rare neoplasm of the kidney that has been recently described. It is almost exclusive to young patients of African descent and associated with sickle cell hemoglobinopathy, mainly sickle cell trait and hemoglobin sickle cell disease. The prognosis of RMC is very poor because of the highly aggressive behavior of this neoplasm and its resistance to conventional chemotherapy. Metastatic disease is almost universal at the time of presentation, and the malignancy is minimally responsive to a variety of regimens and/or modalities, including surgery, radiotherapy, chemotherapy, and biological immune-modulation therapy. We report the seventh case of a left RMC occurring in a white child with sickle cell trait, but with a localization of the tumor in the left kidney, considered a nonpredominant side for this type of tumor.
肾髓质癌(RMC)是一种最近才被描述的罕见肾脏肿瘤。它几乎仅见于非洲裔年轻患者,且与镰状细胞血红蛋白病相关,主要是镰状细胞性状和镰状细胞血红蛋白病。由于这种肿瘤具有高度侵袭性且对传统化疗耐药,RMC的预后非常差。在就诊时几乎普遍存在转移性疾病,并且该恶性肿瘤对包括手术、放疗、化疗和生物免疫调节治疗在内的多种治疗方案和/或方式反应极小。我们报告了第七例发生在一名具有镰状细胞性状的白人儿童中的左肾RMC病例,但肿瘤位于左肾,而左肾被认为是这类肿瘤的非优势侧。